Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is a biopharmaceutical company developing innovative-targeted treatments for patients with cancer who do not have successful therapy choices.

Key Highlights:

• The company is yet to report any revenue from its operations.
• The company's net loss in Q3FY21 was USD 6.42 million, compared to USD 5.54 million in Q3FY20. Since its beginning, the company has incurred net losses, and the prospects aren't looking promising due to a lack of commercial revenues.
• The company is constantly issuing common stock and warrants, diluting existing shareholders' holdings and reducing their ownership in the company.
• Stock is currently trading below its crucial short-term as well as long-term 50-day and 200-day DMA support levels, a bearish indicator.
• Stock is currently leaning towards the lower end of the 52-week range of USD 4.91 to USD 10.30.
• ATNM's share price has declined 34.98% and 21.71% in the past three and six months, respectively.

Three-Year Technical Price Chart (as of January 31, 2022). Analysis by Kalkine Group

Conclusion: The company has not reported any revenues to date. Given the unstable fundamentals, lack of clarity in top-line growth, and bleak outlook, we recommend an "Avoid" rating on the stock at the closing price of USD 5.41, up 3.43%, as of January 31, 2022.

*The reference data in this report has been partly sourced from REFINITIV.

BioSig Technologies, Inc.

BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical device firm in the commercial stage. It works on a unique technological platform to reduce cardiac recordings' noise and artefacts during electrophysiology research and ablation.

Key Highlights:

• The company has just made USD 100 thousand in Q3FY21 vs. nil revenues in Q3FY20.
• The company has posted an operating loss of USD 7.80 million in Q3FY21 vs. USD 13.10 million in Q3FY20.
• As a loss-making enterprise, the company has generated negative EBITDA, operating, and net margins compared to positive industry margins.
• Stock is currently trading below its crucial short-term as well as long-term 50-day and 200-day DMA support levels, a bearish indicator.
• Stock is currently leaning towards the lower end of the 52-week range of USD 1.47 to USD 5.77.
• BSGM's share price has declined 45.23% and 49.43% in the past three and six months, respectively.

Three-Year Technical Price Chart (as of January 31, 2022). Analysis by Kalkine Group

Conclusion: The company has recently started its commercial sales. Given the wobbly fundamentals, lackluster top-line, and gloomy outlook, we recommend an "Avoid" rating on the stock at the closing price of USD 1.78, up 7.88%, as of January 31, 2022.

* The reference data in this report has been partly sourced from REFINITIV.

Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.

Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.

You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.

Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine and its related entities do not hold interests in any of the securities or other financial products covered on the Kalkine website unless those persons comply with certain safeguards, procedures, and disclosures.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.